⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Capulus Therapeutics LLC and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Capulus Therapeutics LLC
↗San Francisco, United States
Capulus Therapeutics is a biotechnology company focused on drug discovery and development using a predictive, artificial intelligence (AI)-guided approach. The company aims to address unmet medical needs by targeting the root causes of diseases, particularly in oncology.
The firm specializes in identifying novel binding pockets and developing small molecule inhibitors. Its research pipeline includes programs targeting the SCAP/SREBP pathway for cancer metabolism and AR-NTD inhibitors for prostate cancer and other indications.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2017
Ownership:private
Status:operating
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Hirdesh Uppal - Co-Founder
Jeffrey N. Lindquist - Co-Founder / Head of Research
Scientific Founders:Hirdesh Uppal, Jeffrey N. Lindquist
LINKS
Website:capulustx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Capulus Therapeutics LLC. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.